Pembrolizumab,Axitinib,Sunitinib,Atezolizumab,Cabozantinib
Merck,Pfizer,roche
['contact-3', 'kn426', 'kn42']
magnificent discussion by placing updated data from kn426, clear and new data release from contact-3. continued questionable durability of io-vegf and lack of benefit of pdl1 post io. #asco2023 
GU medical oncologist @UCSanDiego, mom, wife, avid runner. Kidney and prostate cancer research. Tweets are my own and not medical advice.